Synapse - Joachim Yahalom

Search Within

Joachim Yahalom

Results (56)

PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
Haematologica (2016)

Fulltext@MSK | Save

Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation

Journal Article

Shah, G. L.; Yahalom, J.; Matasar, M. J.; Verwys, S. L.; Goldman, D. A.; Bantilan, K. S.; Zhang, Z.; McCall, S. J.; Moskowitz, A. J.; Moskowitz, C. H.
British Journal of Haematology (2016)

Fulltext@MSK | Save

Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

Journal Article

Qi, S.; Yahalom, J.; Hsu, M.; Chelius, M.; Lunning, M.; Moskowitz, A.; Horwitz, S.
Leukemia and Lymphoma (2016)

Fulltext@MSK | Save

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Journal Article

Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
Blood (2016)

Fulltext@MSK | Save

Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation

Meeting Abstract

Shah, G. L.; Bantilan, K. S.; Verwys, S. L.; McCall, S. J.; Yahalom, J.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.
Blood (2015)

Fulltext@MSK | Save

TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin

Meeting Abstract

Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
Blood (2015)

Fulltext@MSK | Save

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study

Journal Article

Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
Lancet Oncology (2015)

Fulltext@MSK | Save

Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
Blood (2014)

Fulltext@MSK | Save

Modified SMILE (mSMILE) is active in the treatment of extranodal natural killer/T-cell lymphoma: A single center US experience

Meeting Abstract

Lunning, M.; Pamer, E.; Maragulia, J.; Straus, D.; Yahalom, J.; Moskowitz, A.; Zelenetz, A. D.; Horwitz, S.
Clinical Lymphoma, Myeloma and Leukemia (2014)

Fulltext@MSK | Save

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
Blood (2013)

Fulltext@MSK | Save